What is Prelude Therapeutics Incorporated's Market Cap?

Prelude Therapeutics Incorporated's Market Cap is $423.0M, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's Enterprise Value?

Prelude Therapeutics Incorporated's Enterprise Value is $271.2M, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's Price / Sales?

Prelude Therapeutics Incorporated's Price / Sales is 18.9×, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's EV / Revenue?

Prelude Therapeutics Incorporated's EV / Revenue is 12.1×, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's EV / EBITDA?

Prelude Therapeutics Incorporated's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's Revenue (TTM)?

Prelude Therapeutics Incorporated's Revenue (TTM) is $22.4M, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's Net Income (TTM)?

Prelude Therapeutics Incorporated's Net Income (TTM) is -$60.5M, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's EBITDA?

Prelude Therapeutics Incorporated's EBITDA is -$65.8M, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's Diluted EPS (TTM)?

Prelude Therapeutics Incorporated's Diluted EPS (TTM) is -0.76, based on as-reported figures from SEC (XBRL) filings.

What is Prelude Therapeutics Incorporated's EBITDA Margin?

Prelude Therapeutics Incorporated's EBITDA Margin is -293.5%, based on as-reported figures from SEC (XBRL) filings.

Prelude Therapeutics Incorporated (PRLD) Financial Statements

Prelude Therapeutics Incorporated

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG00K7JY2R5

XNAS · usd

5.30▼ 0.16 (-2.93%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close5.46

Day's Range5.19 – 5.46

52-Week Range0.98 – 6.83

Volume257.6K

Avg Volume537.0K

Share Statistics

Shares Outstanding

Employees79

ExchangeXNAS

Listed2020-09-25

Share count as of August 6, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Prelude Therapeutics Incorporated (PRLD)

What is Prelude Therapeutics Incorporated's Market Cap?: Prelude Therapeutics Incorporated's Market Cap is $423.0M, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's Enterprise Value?: Prelude Therapeutics Incorporated's Enterprise Value is $271.2M, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's Price / Sales?: Prelude Therapeutics Incorporated's Price / Sales is 18.9×, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's EV / Revenue?: Prelude Therapeutics Incorporated's EV / Revenue is 12.1×, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's EV / EBITDA?: Prelude Therapeutics Incorporated's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's Revenue (TTM)?: Prelude Therapeutics Incorporated's Revenue (TTM) is $22.4M, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's Net Income (TTM)?: Prelude Therapeutics Incorporated's Net Income (TTM) is -$60.5M, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's EBITDA?: Prelude Therapeutics Incorporated's EBITDA is -$65.8M, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's Diluted EPS (TTM)?: Prelude Therapeutics Incorporated's Diluted EPS (TTM) is -0.76, based on as-reported figures from SEC (XBRL) filings.
What is Prelude Therapeutics Incorporated's EBITDA Margin?: Prelude Therapeutics Incorporated's EBITDA Margin is -293.5%, based on as-reported figures from SEC (XBRL) filings.